SIRT6 Knockout 293T Cell Line

Description

SIRT6 Knockout 293T Cell Line is engineered from human embryonic kidney 293T cells through CRISPR/Cas9-mediated disruption of the Sirtuin 6 (SIRT6) gene, a NAD+-dependent deacetylase and mono-ADP-ribosyltransferase involved in genomic stability, DNA repair, and metabolic regulation. This knockout model exhibits altered stress response and metabolic dysregulation while maintaining 293T cells’ characteristic adherent growth with epithelial morphology and high transfection efficiency. The cell line serves as a powerful tool for studying aging-related processes, cancer metabolism, and inflammatory responses, particularly in research involving telomere maintenance, glycolysis regulation, and NFκB signaling. Maintained at low passage numbers (<P20) with genetic stability, the knockout efficiency is validated through genomic PCR, Sanger sequencing, and Western blot analysis. The cell line has undergone rigorous quality control and is certified free of contamination from HIV-1, HBV, HCV, Syphilis, mycoplasma, fungi, yeast, and bacteria.